Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

被引：10

作者：

Battipaglia, Giorgia ^{[1
]}

Mauff, Katya ^{[2
]}

Wendel, Lotus ^{[3
]}

Angelucci, Emanuele ^{[4
]}

Mohty, Mohamad ^{[5
]}

Arcese, William ^{[6
]}

Santarone, Stella ^{[7
]}

Rubio, Marie Therese ^{[8
,9
]}

Kroger, Nicolaus ^{[10
]}

Fox, Maria Laura ^{[11
]}

Blaise, Didier ^{[12
]}

Iori, Anna Paola ^{[13
]}

Fanin, Renato ^{[14
]}

Chalandon, Yves ^{[15
]}

Pioltelli, Pietro ^{[16
,17
]}

Marotta, Giuseppe ^{[18
]}

Chiusolo, Patrizia ^{[19
,20
]}

Sever, Matjaz ^{[21
,22
]}

Solano, Carlos ^{[23
]}

Contentin, Nathalie ^{[24
]}

de Wreede, Liesbeth C. ^{[25
]}

Czerw, Tomasz ^{[26
]}

Hernandez-Boluda, Juan Carlos ^{[23
]}

Hayden, Patrick ^{[27
]}

McLornan, Donal ^{[28
]}

Yakoub-Agha, Ibrahim ^{[29
]}

机构：

[1] Federico II Univ Naples, Dept Clin Med & Surg, Naples, Italy

[2] EBMT Stat Unit, Leiden, Netherlands

[3] EBMT Data Off, Leiden, Netherlands

[4] IRCCS Osped Policlin San Martino, Genoa, Italy

[5] Sorbonne Univ, Dept Clin Hematol & Cellular Therapy, St Antoine Hosp, AP HP, Paris, France

[6] Univ Tor Vergata, Stem Cell Transplant Unit, Hematol, Rome, Italy

[7] Osped Civile, Dipartimento Ematol Med Trasfus & Biotecnol, Pescara, Italy

[8] CHRU Nancy, Hop Brabois, Dept Hematol, Vendoeuvre Les Nancy, France

[9] Biopole Univ Lorraine, CNRS, UMR 7365, Vendoeuvre Les Nancy, France

[10] Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

[11] Univ Hosp Vall dHebron, Vall dHebron Inst Oncol VHIO, Dept Hematol, Barcelona, Spain

[12] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[13] Univ Sapienza, Dept Translat & Precis Med, Hematol, Rome, Italy

[14] Azienda Sanitaria Univ Integrata Udine, Div Hematol & Stem Cell Transplantat, Udine, Italy

[15] Univ Geneva Hosp, Div Hematol, Geneva, Switzerland

[16] San Gerardo Hosp, Hematol Div, Monza, Italy

[17] San Gerardo Hosp, Bone Marrow Transplantat Unit, Monza, Italy

[18] Azienda Osped Univ Senese, Dept Oncol, UOSA Transplant & Cellular Therapy Ctr, Siena, Italy

[19] Fdn Policlin A Gemelli IRCCS, Rome, Italy

[20] Univ Cattolica Sacro Cuore, Ist Ematol, Rome, Italy

[21] Univ Med Ctr Ljubljana, Dept Hematol, Ljubljana, Slovenia

[22] Univ Ljubljana, Fac Med, Ljubljana, Slovenia

[23] INCLIVA Res Inst, Hosp Clin Univ, Hematol Serv, Valencia, Spain

[24] Ctr Henri Becquerel, Rouen, France

[25] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Gliwice Branch, Dept Bone Marrow Transplantat & Oncohematol, Gliwice, Poland

[27] Trinity Coll Dublin, St Jamess Hosp, Dept Haematol, Dublin, Ireland

[28] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[29] Univ Lille, CHU Lille, INSERM, U1286,Infinite, F-59000 Lille, France

来源：

BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / 07期

关键词：

BONE-MARROW-TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; SURVIVAL; RUXOLITINIB;

D O I：

10.1038/s41409-021-01222-z

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.

引用

页码：1593 / 1602

页数：10

共 40 条

[1] Defining the Intensity of Conditioning Regimens: Working Definitions [J].

Bacigalupo, Andrea ;

Ballen, Karen ;

Rizzo, Doug ;

Giralt, Sergio ;

Lazarus, Hillard ;

Ho, Vincent ;

Apperley, Jane ;

Slavin, Shimon ;

Pasquini, Marcelo ;

Sandmaier, Brenda M. ;

Barrett, John ;

Blaise, Didier ;

Lowski, Robert ;

Horowitz, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633

[2] Outcome of Transplantation for Myelofibrosis [J].

Ballen, Karen K. ;

Shrestha, Smriti ;

Sobocinski, Kathleen A. ;

Zhang, Mei-Jie ;

Bashey, Asad ;

Bolwell, Brian J. ;

Cervantes, Francisco ;

Devine, Steven M. ;

Gale, Robert Peter ;

Gupta, Vikas ;

Hahn, Theresa E. ;

Hogan, William J. ;

Kroeger, Nicolaus ;

Litzow, Mark R. ;

Marks, David I. ;

Maziarz, Richard T. ;

McCarthy, Philip L. ;

Schiller, Gary ;

Schouten, Harry C. ;

Roy, Vivek ;

Wiernik, Peter H. ;

Horowitz, Mary M. ;

Giralt, Sergio A. ;

Arora, Mukta .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) :358-367

[3] Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation [J].

Battipaglia, G. ;

Ruggeri, A. ;

Brissot, E. ;

Mamez, A-C ;

Malard, F. ;

Belhocine, R. ;

Vekhoff, A. ;

Giannotti, F. ;

Ledraa, T. ;

Labopin, M. ;

Rubio, M-T ;

Mohty, M. .

BONE MARROW TRANSPLANTATION, 2015, 50 (12) :1574-1577

[4] Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors [J].

Bregante, Stefania ;

Dominietto, Alida ;

Ghiso, Anna ;

Raiola, Anna Maria ;

Gualandi, Francesca ;

Varaldo, Riccardo ;

Di Grazia, Carmen ;

Lamparelli, Teresa ;

Luchetti, Silvia ;

Geroldi, Simona ;

Casarino, Lucia ;

Pozzi, Sarah ;

Tedone, Elisabetta ;

Van Lint, Maria Teresa ;

Galaverna, Federica ;

Barosi, Giovanni ;

Bacigalupo, Andrea .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (02) :324-329

[5] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [J].

Cervantes, Francisco ;

Dupriez, Brigitte ;

Pereira, Arturo ;

Passamonti, Francesco ;

Reilly, John T. ;

Morra, Enrica ;

Vannucchi, Alessandro M. ;

Mesa, Ruben A. ;

Demory, Jean-Loup ;

Barosi, Giovanni ;

Rumi, Elisa ;

Tefferi, Ayalew .

BLOOD, 2009, 113 (13) :2895-2901

[6] How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? [J].

Chang, Ying-Jun ;

Luznik, Leo ;

Fuchs, Ephraim J. ;

Huang, Xiao-Jun .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[7] Donor Selection in T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies [J].

Ciurea, Stefan O. ;

Champlin, Richard E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) :180-184

[8] Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial [J].

de latour, Regis Peffault ;

Chevret, Sylvie ;

Ruggeri, Anna Lisa ;

Suarez, Felipe ;

Souchet, Laetitia ;

Michonneau, David ;

de Fontbrune, Flore Sicre ;

Coman, Tereza ;

Dhedin, Nathalie ;

Rubio, Marie Therese ;

Nguyen, Stephanie ;

Mohty, Mohamad ;

Socie, Gerard .

BLOOD, 2020, 135 (03) :227-229

[9] Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies [J].

Di Bartolomeo, Paolo ;

Santarone, Stella ;

De Angelis, Gottardo ;

Picardi, Alessandra ;

Cudillo, Laura ;

Cerretti, Raffaella ;

Adorno, Gaspare ;

Angelini, Stefano ;

Andreani, Marco ;

De Felice, Lidia ;

Rapanotti, Maria Cristina ;

Sarmati, Loredana ;

Bavaro, Pasqua ;

Papalinetti, Gabriele ;

Di Nicola, Marta ;

Papola, Franco ;

Montanari, Mauro ;

Nagler, Arnon ;

Arcese, William .

BLOOD, 2013, 121 (05) :849-857

[10]

Fine JP., 2009, J AM STAT ASSOC, V446, P509

← 1 2 3 4 →